The approval was based on a comprehensive clinical data package that included a phase 3 trial comparing denosumab-qbde with Prolia in 473 women with postmenopausal osteoporosis.
The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.
Amgen is celebrating the news that regulators in the USA have given a second green light to the biotech's key compound denosumab. Amgen is celebrating the news that regulators in the USA have given a ...
BENGALURU, India and BRIDGEWATER, N.J., Sept. 17, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback